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Candida parapsilosis species complex
A B S T R A C T
Introduction: Candida parapsilosis (C. parapsilosis) is a common non-albicans Candida species ranked as the
second common cause of bloodstream infections. Azole resistance and elevated echinocandin MICs have
been reported for these fungi. This study was conducted to determine the interactions between azoles
and echinocandins against C. parapsilosis species complex.
Materials and methods: Fifteen fluconazole-resistant clinical isolates of C. parapsilosis complex were
included: C. parapsilosis sensu stricto (n = 7), C. orthopsilosis (n = 5) and C. metapsilosis (n = 3). The activity
of azoles (fluconazole, itraconazole) and echinocandins (anidulafungin, micafungin) alone and in
combination was determined using checkerboard broth microdilution. The results were determined
based on the fractional inhibitory concentration index (FICI).
Results: In vitro combination of fluconazole with anidulafungin was found to be synergistic (FICI 0.07–
0.37) and decreased the MIC range from 4–64 mg/mL to 0.5–16 mg/mL for fluconazole and from
2–8 mg/mL to 0.125–1 mg/mL for anidulafungin. Similarly, interactions of fluconazole with micafungin
(FICI 0.25–0.5), itraconazole with anidulafungin (FICI 0.15–0.37) and itraconazole with micafungin
(FICI 0.09–0.37) were synergistic.
Conclusion: The combination of fluconazole and itraconazole with either anidulafungin or micafungin
demonstrated synergistic interactions against C. parapsilosis species complex, especially against isolates
with elevated MIC values. However, the use of these combinations in clinical practice and the clinical
relevance of in vitro combination results remain unclear.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In recent decades, a global shift from Candida albicans (C. albicans)
to non-albicans Candida species has been reported [1]. Candida
parapsilosis (C. parapsilosis) is a non-albicans species serving as the
second most common cause of bloodstream infections, preceded by* Corresponding author at: Department of Medical Parasitology and Mycology,
School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
E-mail address: skhodavaisy@sina.tums.ac.ir (S. Khodavaisy).
http://dx.doi.org/10.1016/j.jgar.2019.11.003
2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published by
creativecommons.org/licenses/by-nc-nd/4.0/).C. albicans [2]. It has also been found to be as common as C. albicans
among cases of invasive candidiasis in Serbia [3] and as the leading
cause of candidaemia before 2010 in Europe [4], Asia [5], South
America [6], and after 2010 in Iran [7], Venezuela and Colombia [8].
Using molecular analysis, C. parapsilosis was found to be a complex
of three cryptic species: C. parapsilosis sensu stricto, C. orthopsilosis
and C. metapsilosis [9]. C. parapsilosis is able to produce biofilm on
catheters and other medical devices, leading to increased resistance
to azole antifungal drugs [2,10]. It also tends to persist in the hospital
environment and has frequently been isolated from hospital
surfaces and the hands of healthcare workers [11,12], which may Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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of C. parapsilosis outbreaks in intensive care units, which is
indicative of exogenous transmission of this pathogen through
direct and indirect contact by healthcare workers’ hands [13–15].
Although members of C. parapsilosis complex are usually suscepti-
ble to azole antifungals [16], resistance has also been reported [17].
In a recent study, 27.6% (55/199) and 4.5% (9/199) of C. parapsilosis
sensu stricto isolates were resistant and susceptible dose-
dependent to fluconazole, respectively [18]. Echinocandins are
recommend by the Infectious Diseases Society of America for
treatment of candidiasis, while elevated MICs to this class of
antifungals have consistently been reported in the C. parapsilosis
species complex [19,20]. A promising way to deal with drug
resistance in fungi is to use combinations of antifungal drugs,
particularly those with different mechanisms of action to reduce the
toxicity and side effects by shortening the duration of treatment
[21]. Combination of echinocandins with azoles could be attractive
as they have different targets and mechanisms of action. Therefore,
this study investigated the combination of echinocandins with
triazoles against fluconazole-resistant C. parapsilosis complex
clinical isolates.
2. Materials and methods
2.1. Fungal isolates
Fifteen fluconazole-resistant clinical isolates of C. parapsilosis
complex – including C. parapsilosis sensu stricto (n = 7),
C. orthopsilosis (n = 5) and C. metapsilosis (n = 3) – were included
in this study. All the isolates were previously identified by matrix-
assisted laser desorption ionization-time of flight mass spectrom-
etry (MALDI-TOF) and confirmed by molecular methods
(i.e. sequencing of internal transcribed spacer ribosomal DNA
and D1/D2 regions).
2.2. Antifungal drugs
Stock solutions of antifungal drugs were made by dissolving
fluconazole (Pfizer Central Research, Sandwich, UK) in sterile
double-distilled water, and itraconazole (Janssen Research Founda-
tion, Beerse, Belgium), anidulafungin (Pfizer Central Research,
Sandwich, United Kingdom) and micafungin (Merck Sharp & Dohme,
Haarlem, Netherlands) in dimethyl sulfoxide (DMSO). WorkingTable 1
The MICs of azoles and echinocandins alone and in combination against Candida parap
Strain No. MICs alone (mg/mL) MICs in combination (mg/mL
FLC ITC ANF MCF FLC/ANF FLC/MCF IT
Candida parapsilosis sensu stricto
TMML 1296 32 4 8 1 4/0.5 8/0.125 0.
TMML 1297 32 4 8 2 8/0.5 4/0.25 1/
TMML 1298 64 2 2 2 4/0.25 16/0.125 0.
TMML 1299 32 4 4 1 8/0.5 2/0.25 1/
TMML 1300 64 2 8 2 16/1 16/0.25 0.
TMML 1301 64 4 8 1 4/0.125 8/0.125 0.
TMML 1302 32 4 2 2 8/0.25 8/0.25 1/
Candida orthopsilosis
TMML 399 8 1 4 4 0.5/0.25 1/0.25 0.
TMML 406 16 1 8 4 4/0.5 4/0.5 0.
TMML 407 16 2 8 2 4/0.25 4/0.25 0.
TMML 414 8 2 4 4 1/0.25 2/1 0.
TMML 443 16 1 4 4 4/0.5 4/0.125 0.
Candida metapsilosis
TMML 469 4 1 2 1 1/0.125 1/0.125 0.
TMML 470 4 1 4 1 1/0.5 0.5/0.125 0.
TMML 471 4 1 4 2 0.5/1 1/0.125 0.
Abbreviations: FLC, fluconazole; ITC, itraconazole; ANF, anidulafungin; MCF, micafungisolutions at 4X the final concentrations were prepared in RPMI 1640
with glutamine, but without NaHCO3 as recommended by the
Clinical Laboratory Standards Institute (CLSI) M27-A3 [22]. The final
concentrations ranged from 0.125– 64 mg/mL for fluconazole, 0.03–
16 mg/mL for itraconazole and 0.125– 8 mg/mL for echinocandins.
2.3. In vitro combination testing
In vitro interaction of azoles with echinocandins (i.e. flucona-
zole with anidulafungin, fluconazole with micafungin, itraconazole
with anidulafungin, and itraconazole with micafungin) were
studied using a microdilution checkerboard technique [23]. For
preparation of test microplates, 50 mL of each concentration of
azoles (fluconazole or itraconazole) were added to columns 1–10,
and then 50 mL of echinocandins (anidulafungin or micafungin)
were added to rows A–G. Row H and column 11 contained the
azoles and echinocandins alone, respectively. Column 12 was the
drug-free well that served as the growth control. Fungal inoculum
was prepared following the CLSI M27-A3 [24] and 100 mL of it was
dispensed to all the wells of test microplates. After 24 h of
incubation at 35 C, the results were visually read. To assess the
interaction outcomes, the fractional inhibitory concentration index
(FICI) value was calculated as follows: (MIC of Drug A in
combination/MIC of Drug A alone) + (MIC of Drug B in
combination/MIC of Drug B alone). The interaction was considered
to be a synergistic effect when the FICI was 0.5, indifferent at >0.5
to <4.0, and antagonistic at 4.
3. Results
The results of in vitro combination testing of fluconazole and
itraconazole with echinocandins are summarised in Table 1. The
MIC ranges of fluconazole when tested alone against C. parapsilosis
sensu stricto, C. orthopsilosis and C. metapsilosis isolates were 32–
64 mg/mL, 8–16 mg/mL and 4 mg/mL, respectively. The combina-
tion of fluconazole with anidulafungin resulted in a synergistic
interaction (FICI range 0.07–0.37) and decreased the MIC range of
fluconazole to 4–16 mg/mL against C. parapsilosis sensu stricto,
0.5–4 mg/mL against C. orthopsilosis and 0.5–1 mg/mL against
C. metapsilosis (Table 1). Similarly, fluconazole combined with
micafungin interacted synergistically (FICI range 0.25–0.5) and
reduced the MIC range of fluconazole to 2–16 mg/mL against
C. parapsilosis, 1–4 mg/mL against C. orthopsilosis and 0.5–1 mg/mLsilosis species complex.
) FICI/interpretation
C/ANF ITC/MCF FLC/ANF FLC/MCF ITC/ANF ITC/MCF
5/1 0.25/0.125 0.18/SYN 0.37/SYN 0.25/SYN 0.18/SYN
1 1/0.25 0.31/SYN 0.25/SYN 0.37/SYN 0.37/SYN
5/0.25 0.25/0.25 0.18/SYN 0.31/SYN 0.37/SYN 0.25/SYN
0.5 0.5/0.25 0.37/SYN 0.31/SYN 0.37/SYN 0.37/SYN
5/0.5 0.5/0.25 0.37/SYN 0.37/SYN 0.31/SYN 0.37/SYN
5/1 1/0.125 0.07/SYN 0.25/SYN 0.25/SYN 0.37/SYN
0.25 0.25/0.5 0.37/SYN 0.37/SYN 0.37/SYN 0.31/SYN
06/0.5 0.25/0.25 0.12/SYN 0.18/SYN 0.18/SYN 0.31/SYN
25/0.25 0.06/0.25 0.31/SYN 0.37/SYN 0.28/SYN 0.12/SYN
5/1 0.5/0.125 0.28/SYN 0.37/SYN 0.37/SYN 0.31/SYN
5/0.125 0.5/0.25 0.18/SYN 0.5/SYN 0.28/SYN 0.31/SYN
125/0.25 0.03/0.25 0.37/SYN 0.28/SYN 0.18/SYN 0.09/SYN
03/0.25 0.06/0.125 0.31/SYN 0.37/SYN 0.15/SYN 0.18/SYN
06/0.5 0.25/0.125 0.37/SYN 0.25/SYN 0.18/SYN 0.37/SYN
125/0.25 0.25/0.25 0.37/SYN 0.31/SYN 0.18/SYN 0.37/SYN
n; FICI, fractional inhibitory concentration index; SYN, synergism.
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when tested alone was found to be 2–4 mg/mL against
C. parapsilosis sensu stricto, 1–2 mg/mL against C. orthopsilosis
and 1 mg/mL against C. metapsilosis. In combination with
anidulafungin or micafungin, the MIC range of itraconazole
decreased to 0.5–1 mg/mL and 0.25–1 mg/mL against C. parapsilosis
sensu stricto, 0.06–0.5 mg/mL and 0.03–0.5 mg/mL against
C. orthopsilosis and 0.03–0.125 mg/mL and 0.06–0.25 mg/mL
against C. metapsilosis, respectively.
3.1. Discussion
The prophylactic use of azole antifungal drugs, particularly
fluconazole, since the late 1990s, significantly reduced the
incidence and mortality of systemic Candida infections. However,
as a consequence, it led to a shift from fluconazole-susceptible to
fluconazole-resistant infections, especially due to non-albicans
Candida species [24]. C. parapsilosis is one of the common non-
albicans Candida species able to form biofilms on catheters and
other medical devices and can be transmitted horizontally in
healthcare facilities. It is a big threat for patients in intensive care
units and a known cause of candidaemia in susceptible paediatric
patients [25–28]. Nosocomial outbreaks due to this species have
been reported in different geographical regions [13,29–31]. Azole-
resistance has been reported in C. parapsilosis, especially among
cases of invasive infections and those previously treated with
fluconazole [18,32,33]. This resistance can also be acquired during
systemic antifungal therapy [34,35]. Although echinocandins have
been recommended as first-line treatment for invasive candidiasis,
reports have shown that C. parapsilosis has higher MICs than other
Candida species to echinocandins [20,36]. An alternative method
for treatment of resistant cases is the use of a combination of two
drugs with different mechanisms of action [21], which needs in
vitro and animal model studies prior to being used in a clinical
setting.
In the present study, the antifungal activity of triazoles
(itraconazole, fluconazole) combined with echinocandins
(anidulafungin, micafungin) was determined on fluconazole-
resistant C. parapsilosis complex isolates. The results showed
synergism for all combinations. Antifungal interactions may be
different depending on the antifungal classes. In a recent study
Chassot et al. investigated the combinations of amphotericin B,
fluconazole, voriconazole and flucytosine against echinocandin-
susceptible and echinocandin-resistant C. parapsilosis sensu stricto
strains and, unlike the current results, most of the interactions
were indifferent [37]. Variations of in vitro interactions can also
occur and members within an antifungal class do not necessarily
interact in the same way. Combinations of posaconazole with
either caspofungin or anidulafungin and voriconazole with
anidulafungin were found to be indifferent, while voriconazole
with caspofungin resulted in an antagonistic interaction against
C. parapsilosis sensu stricto isolates [38]. Moreover, voriconazole in
combination with micafungin exhibited a synergistic interaction
against the emerging pathogen C. auris, while the interaction of
voriconazole with caspofungin and fluconazole with either
caspofungin or anidulafungin was indifferent [39]. Although
inter-species variations have been reported for the results of
antifungal combinations [40], no difference was noted in
the current results obtained for C. parapsilosis sensu stricto,
C. orthopsilosis and C. metapsilosis. This might be due to the close
relatedness of these species, which belong to the same phyloge-
netic complex. However, this finding is based on a limited number
of isolates and because there are no other data on the combination
of antifungal drugs against C. orthopsilosis and C. metapsilosis,
future studies in this area may change our understanding.In conclusion, the combination of fluconazole or itraconazole
with either anidulafungin or micafungin showed a synergistic
interaction against the C. parapsilosis species complex, especially
against isolates with elevated MIC values. The use of these
combinations in clinical practice and the clinical relevancy of these
in vitro results should be further explored.
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